• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

GT Biopharma Must Learn How to Play the Game ... and Explain Itself

Let's look at the rookie mistake the biopharma made on Monday, and what makes the company still hold promise for investors -- if it explains its C-suite moves.
By TIMOTHY COLLINS
Nov 08, 2021 | 02:32 PM EST
Stocks quotes in this article: GTBP

GT Biopharma ( GTBP) , you need to be better than this.
 
The press release put out on Monday was a rookie mistake.
 
Before I get into that, I still believe in the science behind the company, the data continues to be strong, and those on the science side of the business are remaining with the company. This clinical stage biopharmaceutical company is focused developing immuno-oncology therapies.
 
The problem now, though, is announcing a "transition" of CEO and CFO in a cookie cutter press release.
 
Younger biotechs often have a change at the top. Often, the first person in the C-suite is a founder of the science, but that person may not be acclimated or have the time for capital raising and the Wall Street schmoozing that is necessary. That may sound cliche, but it is true. The move for many companies, not just biotechs, is to bring in a front person that has experience raising capital, knows what to say and when to say, and can play to the crowd.
 
Once a company begins to mature and grow into its own, a transition to a new CEO, one less forward facing and more inward business facing, is quite common. What's not as common is when both the CEO and CFO are "transitioned" and done so out of blue. Even when a CEO is changed, many investors and traders can get past that, but when a CFO is shown the door without an immediate and suitable replacement, it better come with a darned good explanation or investors will immediately flee.
 
That's the case with GTBP.
 
Unanticipated CFP departures can be yellow flags. When they come without explanation, they can be red flags. Even, if in the end, there's a justifiable reason, when it is not provided initially investors will shoot first and ask questions later. The first hour of trading showed us that very well on Monday. For dip buyers, you have the low around $4.50 as your clear stop now. A decent explanation from the company could get this back into the low $6s.
 
I would expect, or at least hope, we'll get one this week. If they opt to say nothing further, then I suspect we'll test that $4.50 level again.
 
We were fortunate to first grab this one under $5, take off all the initial risk capital plus some, when it ran up into the teens, and maintain a position with less stress. That said, no one likes to watch a holding fall 20% or 30% after it has already fallen 66% off its highs.
 
Is it worth a shot down here? The trader in me thinks that the $4.50 level will hold, so if you are willing to risk $0.80 per share, then yes. But that's a big number in terms of percentages. There is still warrant hangover around $5.50, so I prefer to see us close over that level.
 
For my remaining shares, I'm going to set a stop on a close below $4.50. I am not adding, though. While I think this won't come down to accounting irregularities, it would be throwing good money after bad without knowing for certain. My gut says the news isn't disastrous, but the way in which it was disseminated fails to bring much confidence, so I have enough room to give existing shares a chance but not enough to add more without a close over $5.50.
 
Please note that due to factors including low market capitalization and/or insufficient public float, we consider GTBP to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Tim Collins was long GTBP.

TAGS: Investing | Options | Stocks | Biotechnology | Pharmaceuticals

More from Stocks

This Is No Time to Put Money to Work

James "Rev Shark" DePorre
Oct 2, 2023 4:04 PM EDT

The government shutdown deal did little to move stocks on Monday after the open.

Microsoft: Will Strength or Weakness Win Out?

Bruce Kamich
Oct 2, 2023 2:26 PM EDT

Let's check the charts and indicators.

Trading Coinbase Is More Than Just a Flip of the Coin

Bruce Kamich
Oct 2, 2023 1:30 PM EDT

The stock rallied early Monday, but those gains are fading.

Oil's on the Front Burner, and It's Getting Overcooked

Peter Tchir
Oct 2, 2023 12:30 PM EDT

Let me show you with one simple chart why the moves in this energy commodity are overhyped.

The Magnificent Seven Are Regaining Momentum

James "Rev Shark" DePorre
Oct 2, 2023 11:50 AM EDT

I have taken a position in one of these 'magnificent' names, and have my eyes on an under-the-radar asset manager.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login